Ratings ZIVO Bioscience, Inc.

Equities

ZIVO

US98978N3098

Market Closed - OTC Markets Other stock markets 12:20:35 2024-04-26 pm EDT			5-day change	1st Jan Change
8.1 ^USD	+1.25%		+1.25%	+575.00%

Mar. 15	ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Food Processing

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ZIVO BIOSCIENCE, INC.	+575.00%	22.7M		-
ZHEJIANG NHU COMPANY LTD.	+8.20%	7.78B		D+
BELLRING BRANDS, INC.	+0.34%	7.38B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+10.20%	6.52B		-
BYHEALTH CO., LTD	-8.10%	3.67B		D
XIAMEN KINGDOMWAY GROUP COMPANY	-14.57%	1.17B	-	-
SIRIO PHARMA CO., LTD.	+8.34%	934M		-
HERBALIFE LTD.	-42.27%	879M		B+
USANA HEALTH SCIENCES, INC.	-18.90%	836M		C+
JAMIESON WELLNESS INC.	-16.45%	802M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes